Related news from
Tue, 03 Feb 2026 03:06:18 +0000	Cencora (COR) Reports Earnings Tomorrow: What To Expect Healthcare distributor Cencora (NYSE:COR) will be reporting results this Wednesday before market open. Here’s what to look for.
Sun, 01 Feb 2026 12:47:23 +0000	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week Crucial labor market data, more earnings from Big Tech giants, and continued discussion over where Kevin Warsh may lead the central bank should set the agenda in the week ahead.
Sat, 31 Jan 2026 14:36:00 +0000	Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]
Sat, 31 Jan 2026 07:05:31 +0000	How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...
Fri, 30 Jan 2026 14:15:07 +0000	Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Thu, 29 Jan 2026 14:35:11 +0000	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls
Thu, 29 Jan 2026 13:33:00 +0000	Can Specialty and International Momentum Support Cencora's Q1 Results? COR's Q1 outlook is supported by specialty utilization, RCA momentum, and steady international growth, even as GLP-1 tailwinds ease.
Mon, 26 Jan 2026 18:27:34 +0000	IBD Stock Of The Day: Why Cardinal Health's Momentum Is 'Special' — And Not Over Yet Cardinal Health is Monday's IBD Stock Of The Day. Shares are rebounding off their 21-day line, helped by continued biopharma momentum.
Sun, 25 Jan 2026 09:46:28 +0000	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI Investing.com -- Blue chip stocks in the healthcare sector are showing exceptional growth potential according to recent rankings from WarrenAI. The analysis highlights four standout companies that combine strong fundamentals with significant upside potential, making them attractive options in today’s market.
Sat, 24 Jan 2026 14:06:34 +0000	Assessing Cencora (COR) Valuation After Strong Returns And Conflicting Fair Value Signals What Cencora’s Recent Share Moves Signal for Investors Cencora (COR) has caught investor attention after a steady run, with the stock closing at $353.48 and showing positive total returns over the past year and over the past 3 months. The company reports annual revenue of about $321.3b and net income of $1.6b, alongside annual revenue growth of 6.2% and net income growth of 17.4%. These figures give investors concrete fundamentals to weigh against recent share performance. See our latest...
Thu, 22 Jan 2026 14:00:00 +0000	Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products ATLANTA, January 22, 2026--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products.
Thu, 22 Jan 2026 12:30:00 +0000	Cencora Elects Ellen Cooper to Its Board of Directors CONSHOHOCKEN, Pa., January 22, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026.
Mon, 12 Jan 2026 17:47:53 +0000	Jim Cramer Says “Cardinal Is Really the Monster” Among Drug Distributors Cardinal Health, Inc. (NYSE:CAH) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer highlighted the company’s noteworthy performance, as he commented: “The drug distributors continue to relentlessly climb higher. There’s nothing, you know, people hate the pharma middleman. Even the president doesn’t talk, like… them. But I got to […]
Mon, 12 Jan 2026 12:51:00 +0000	3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.
Fri, 09 Jan 2026 18:13:53 +0000	Cencora (COR) Valuation Check As Share Price Momentum Cools After Recent Gains Cencora (COR) shares have been relatively muted recently, with a 1-day decline of about 1% and a roughly flat return over the past month, even as the stock shows a strong total return over the past year. See our latest analysis for Cencora. The recent softness in Cencora’s share price, with the stock now at $335.74 and a small 90 day share price gain, contrasts with its much stronger 1 year and multi year total shareholder returns. This suggests momentum has cooled even as long term holders...
Fri, 09 Jan 2026 14:06:54 +0000	What to Expect From Cencora's Next Quarterly Earnings Report Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.
Thu, 08 Jan 2026 12:57:00 +0000	Here's Why You Should Retain Cencora Stock in Your Portfolio Now Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.
Wed, 07 Jan 2026 04:36:04 +0000	3 Healthcare Stocks with Exciting Potential Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.
Tue, 06 Jan 2026 21:30:00 +0000	Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release CONSHOHOCKEN, Pa., January 06, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.
Mon, 05 Jan 2026 18:44:00 +0000	McKesson Builds Earnings Momentum on Specialty and Automation McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!